Low suspicion lesions on multiparametric magnetic resonance imaging predict for the absence of high‐risk prostate cancer
Study Type – Diagnostic (case series) Level of Evidence 4 What's known on the subject? and What does the study add? Over‐treatment of indolent prostate cancer lesions is a problem which can result in increased human and medical costs. Lesions with a low suspician level at mpMRI of the prostate...
Saved in:
| Published in | BJU international Vol. 110; no. 11b; pp. E783 - E788 |
|---|---|
| Main Authors | , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Wiley Subscription Services, Inc
01.12.2012
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1464-4096 1464-410X 1464-410X |
| DOI | 10.1111/j.1464-410X.2012.11646.x |
Cover
| Abstract | Study Type – Diagnostic (case series)
Level of Evidence 4
What's known on the subject? and What does the study add?
Over‐treatment of indolent prostate cancer lesions is a problem which can result in increased human and medical costs.
Lesions with a low suspician level at mpMRI of the prostate have low risk of including high risk prostate cancer.
Objective
To determine whether multiparametric magnetic resonance imaging (mpMRI) has the potential to identify patients at low risk for cancer, thus obviating the need for biopsy. Prostate cancer is currently diagnosed by random biopsies, resulting in the discovery of multiple low‐risk cancers that often lead to overtreatment.
Patients and Methods
We reviewed 800 consecutive patients who underwent a 3 Tesla mpMRI of the prostate with an endorectal coil from March 2007 to November 2011.
All suspicious lesions were independently reviewed by two radiologists using T2‐weighted, diffusion‐weighted, spectroscopic and dynamic contrast‐enhanced MRI sequences.
Patients with only low suspicion lesions (maximum of two positive parameters on mpMRI) who subsequently underwent transrectal ultrasonography (TRUS)/MRI fusion targeted biopsy were selected for analysis.
Results
In total, 125 patients with only low suspicion prostatic lesions on mpMRI were identified.
On TRUS/MRI fusion biopsy, 77 (62%) of these patients had no cancer detected, 38 patients had Gleason 6 disease and 10 patients had Gleason 7 (3+4) disease.
There were 30 patients with cancer detected on biopsy who qualified for active surveillance using 2011 National Comprehensive Cancer Network guidelines.
No cases of high‐risk (≥ Gleason 4+3) cancer were identified on biopsy and, of the fifteen patients who underwent radical prostatectomy at our institution, none were pathologically upgraded to high‐risk cancer.
Thus, for patients with only low suspicion lesions, 107 (88%) patients either had no cancer or clinically insignificant disease.
Conclusions
The results obtained in the present study show that low suspicion lesions on mpMRI are associated with either negative biopsies or low‐grade tumours suitable for active surveillance.
Such patients have a low risk of harbouring high‐risk prostate cancers. |
|---|---|
| AbstractList | What's known on the subject? and What does the study add? Over-treatment of indolent prostate cancer lesions is a problem which can result in increased human and medical costs. Lesions with a low suspician level at mpMRI of the prostate have low risk of including high risk prostate cancer.UNLABELLEDWhat's known on the subject? and What does the study add? Over-treatment of indolent prostate cancer lesions is a problem which can result in increased human and medical costs. Lesions with a low suspician level at mpMRI of the prostate have low risk of including high risk prostate cancer.To determine whether multiparametric magnetic resonance imaging (mpMRI) has the potential to identify patients at low risk for cancer, thus obviating the need for biopsy. Prostate cancer is currently diagnosed by random biopsies, resulting in the discovery of multiple low-risk cancers that often lead to overtreatment.OBJECTIVETo determine whether multiparametric magnetic resonance imaging (mpMRI) has the potential to identify patients at low risk for cancer, thus obviating the need for biopsy. Prostate cancer is currently diagnosed by random biopsies, resulting in the discovery of multiple low-risk cancers that often lead to overtreatment.We reviewed 800 consecutive patients who underwent a 3 Tesla mpMRI of the prostate with an endorectal coil from March 2007 to November 2011. All suspicious lesions were independently reviewed by two radiologists using T2-weighted, diffusion-weighted, spectroscopic and dynamic contrast-enhanced MRI sequences. Patients with only low suspicion lesions (maximum of two positive parameters on mpMRI) who subsequently underwent transrectal ultrasonography (TRUS)/MRI fusion targeted biopsy were selected for analysis.PATIENTS AND METHODSWe reviewed 800 consecutive patients who underwent a 3 Tesla mpMRI of the prostate with an endorectal coil from March 2007 to November 2011. All suspicious lesions were independently reviewed by two radiologists using T2-weighted, diffusion-weighted, spectroscopic and dynamic contrast-enhanced MRI sequences. Patients with only low suspicion lesions (maximum of two positive parameters on mpMRI) who subsequently underwent transrectal ultrasonography (TRUS)/MRI fusion targeted biopsy were selected for analysis.In total, 125 patients with only low suspicion prostatic lesions on mpMRI were identified. On TRUS/MRI fusion biopsy, 77 (62%) of these patients had no cancer detected, 38 patients had Gleason 6 disease and 10 patients had Gleason 7 (3+4) disease. There were 30 patients with cancer detected on biopsy who qualified for active surveillance using 2011 National Comprehensive Cancer Network guidelines. No cases of high-risk (≥ Gleason 4+3) cancer were identified on biopsy and, of the fifteen patients who underwent radical prostatectomy at our institution, none were pathologically upgraded to high-risk cancer. Thus, for patients with only low suspicion lesions, 107 (88%) patients either had no cancer or clinically insignificant disease.RESULTSIn total, 125 patients with only low suspicion prostatic lesions on mpMRI were identified. On TRUS/MRI fusion biopsy, 77 (62%) of these patients had no cancer detected, 38 patients had Gleason 6 disease and 10 patients had Gleason 7 (3+4) disease. There were 30 patients with cancer detected on biopsy who qualified for active surveillance using 2011 National Comprehensive Cancer Network guidelines. No cases of high-risk (≥ Gleason 4+3) cancer were identified on biopsy and, of the fifteen patients who underwent radical prostatectomy at our institution, none were pathologically upgraded to high-risk cancer. Thus, for patients with only low suspicion lesions, 107 (88%) patients either had no cancer or clinically insignificant disease.The results obtained in the present study show that low suspicion lesions on mpMRI are associated with either negative biopsies or low-grade tumours suitable for active surveillance. Such patients have a low risk of harbouring high-risk prostate cancers.CONCLUSIONSThe results obtained in the present study show that low suspicion lesions on mpMRI are associated with either negative biopsies or low-grade tumours suitable for active surveillance. Such patients have a low risk of harbouring high-risk prostate cancers. Study Type – Diagnostic (case series) Level of Evidence 4 What's known on the subject? and What does the study add? Over‐treatment of indolent prostate cancer lesions is a problem which can result in increased human and medical costs. Lesions with a low suspician level at mpMRI of the prostate have low risk of including high risk prostate cancer. Objective To determine whether multiparametric magnetic resonance imaging (mpMRI) has the potential to identify patients at low risk for cancer, thus obviating the need for biopsy. Prostate cancer is currently diagnosed by random biopsies, resulting in the discovery of multiple low‐risk cancers that often lead to overtreatment. Patients and Methods We reviewed 800 consecutive patients who underwent a 3 Tesla mpMRI of the prostate with an endorectal coil from March 2007 to November 2011. All suspicious lesions were independently reviewed by two radiologists using T2‐weighted, diffusion‐weighted, spectroscopic and dynamic contrast‐enhanced MRI sequences. Patients with only low suspicion lesions (maximum of two positive parameters on mpMRI) who subsequently underwent transrectal ultrasonography (TRUS)/MRI fusion targeted biopsy were selected for analysis. Results In total, 125 patients with only low suspicion prostatic lesions on mpMRI were identified. On TRUS/MRI fusion biopsy, 77 (62%) of these patients had no cancer detected, 38 patients had Gleason 6 disease and 10 patients had Gleason 7 (3+4) disease. There were 30 patients with cancer detected on biopsy who qualified for active surveillance using 2011 National Comprehensive Cancer Network guidelines. No cases of high‐risk (≥ Gleason 4+3) cancer were identified on biopsy and, of the fifteen patients who underwent radical prostatectomy at our institution, none were pathologically upgraded to high‐risk cancer. Thus, for patients with only low suspicion lesions, 107 (88%) patients either had no cancer or clinically insignificant disease. Conclusions The results obtained in the present study show that low suspicion lesions on mpMRI are associated with either negative biopsies or low‐grade tumours suitable for active surveillance. Such patients have a low risk of harbouring high‐risk prostate cancers. What's known on the subject? and What does the study add? Over-treatment of indolent prostate cancer lesions is a problem which can result in increased human and medical costs. Lesions with a low suspician level at mpMRI of the prostate have low risk of including high risk prostate cancer. To determine whether multiparametric magnetic resonance imaging (mpMRI) has the potential to identify patients at low risk for cancer, thus obviating the need for biopsy. Prostate cancer is currently diagnosed by random biopsies, resulting in the discovery of multiple low-risk cancers that often lead to overtreatment. We reviewed 800 consecutive patients who underwent a 3 Tesla mpMRI of the prostate with an endorectal coil from March 2007 to November 2011. All suspicious lesions were independently reviewed by two radiologists using T2-weighted, diffusion-weighted, spectroscopic and dynamic contrast-enhanced MRI sequences. Patients with only low suspicion lesions (maximum of two positive parameters on mpMRI) who subsequently underwent transrectal ultrasonography (TRUS)/MRI fusion targeted biopsy were selected for analysis. In total, 125 patients with only low suspicion prostatic lesions on mpMRI were identified. On TRUS/MRI fusion biopsy, 77 (62%) of these patients had no cancer detected, 38 patients had Gleason 6 disease and 10 patients had Gleason 7 (3+4) disease. There were 30 patients with cancer detected on biopsy who qualified for active surveillance using 2011 National Comprehensive Cancer Network guidelines. No cases of high-risk (≥ Gleason 4+3) cancer were identified on biopsy and, of the fifteen patients who underwent radical prostatectomy at our institution, none were pathologically upgraded to high-risk cancer. Thus, for patients with only low suspicion lesions, 107 (88%) patients either had no cancer or clinically insignificant disease. The results obtained in the present study show that low suspicion lesions on mpMRI are associated with either negative biopsies or low-grade tumours suitable for active surveillance. Such patients have a low risk of harbouring high-risk prostate cancers. Study Type - Diagnostic (case series) Level of Evidence-4 What's known on the subject? and What does the study add? Over-treatment of indolent prostate cancer lesions is a problem which can result in increased human and medical costs. Lesions with a low suspician level at mpMRI of the prostate have low risk of including high risk prostate cancer. Objective To determine whether multiparametric magnetic resonance imaging (mpMRI) has the potential to identify patients at low risk for cancer, thus obviating the need for biopsy. Prostate cancer is currently diagnosed by random biopsies, resulting in the discovery of multiple low-risk cancers that often lead to overtreatment. Patients and Methods We reviewed 800 consecutive patients who underwent a 3 Tesla mpMRI of the prostate with an endorectal coil from March 2007 to November 2011. All suspicious lesions were independently reviewed by two radiologists using T2-weighted, diffusion-weighted, spectroscopic and dynamic contrast-enhanced MRI sequences. Patients with only low suspicion lesions (maximum of two positive parameters on mpMRI) who subsequently underwent transrectal ultrasonography (TRUS)/MRI fusion targeted biopsy were selected for analysis. Results In total, 125 patients with only low suspicion prostatic lesions on mpMRI were identified. On TRUS/MRI fusion biopsy, 77 (62%) of these patients had no cancer detected, 38 patients had Gleason 6 disease and 10 patients had Gleason 7 (3+4) disease. There were 30 patients with cancer detected on biopsy who qualified for active surveillance using 2011 National Comprehensive Cancer Network guidelines. No cases of high-risk ( Gleason 4+3) cancer were identified on biopsy and, of the fifteen patients who underwent radical prostatectomy at our institution, none were pathologically upgraded to high-risk cancer. Thus, for patients with only low suspicion lesions, 107 (88%) patients either had no cancer or clinically insignificant disease. Conclusions The results obtained in the present study show that low suspicion lesions on mpMRI are associated with either negative biopsies or low-grade tumours suitable for active surveillance. Such patients have a low risk of harbouring high-risk prostate cancers [PUBLICATION ABSTRACT]. |
| Author | Pinto, Peter A. Wood, Bradford J. Yerram, Nitin K. Hoang, Anthony N. Choyke, Peter L. Volkin, Dmitry Vourganti, Srinivas Gupta, Gopal N. Linehan, W. Marston Nix, Jeffrey Turkbey, Baris |
| AuthorAffiliation | 2 Center for Interventional Oncology, Department of Radiology and Imaging Sciences, National Institutes of Health, Bethesda MD 3 Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda MD 1 Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda MD |
| AuthorAffiliation_xml | – name: 3 Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda MD – name: 1 Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda MD – name: 2 Center for Interventional Oncology, Department of Radiology and Imaging Sciences, National Institutes of Health, Bethesda MD |
| Author_xml | – sequence: 1 givenname: Nitin K. surname: Yerram fullname: Yerram, Nitin K. organization: National Cancer Institute – sequence: 2 givenname: Dmitry surname: Volkin fullname: Volkin, Dmitry organization: National Cancer Institute – sequence: 3 givenname: Baris surname: Turkbey fullname: Turkbey, Baris organization: National Institutes of Health – sequence: 4 givenname: Jeffrey surname: Nix fullname: Nix, Jeffrey organization: National Cancer Institute – sequence: 5 givenname: Anthony N. surname: Hoang fullname: Hoang, Anthony N. organization: National Cancer Institute – sequence: 6 givenname: Srinivas surname: Vourganti fullname: Vourganti, Srinivas organization: National Cancer Institute – sequence: 7 givenname: Gopal N. surname: Gupta fullname: Gupta, Gopal N. organization: National Cancer Institute – sequence: 8 givenname: W. Marston surname: Linehan fullname: Linehan, W. Marston organization: National Cancer Institute – sequence: 9 givenname: Peter L. surname: Choyke fullname: Choyke, Peter L. organization: National Institutes of Health – sequence: 10 givenname: Bradford J. surname: Wood fullname: Wood, Bradford J. organization: Center for Interventional Oncology – sequence: 11 givenname: Peter A. surname: Pinto fullname: Pinto, Peter A. organization: Center for Interventional Oncology |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23130821$$D View this record in MEDLINE/PubMed |
| BookMark | eNqVUsuOEzEQtNAi9gG_gCxx4ZLgx9iZuSDBChZQJC6stDfLY_ckDhN7sGdIwmk_gW_kS_BsdsNDAoEv3eruKleXfYqOfPCAEKZkSvN5tprSQhaTgpKrKSOU5aos5HR7D50cGkd3OankMTpNaUVILkjxAB0zTjkpGT1BX-Zhg9OQOmdc8LiFlEPCOV0Pbe86HfUa-ugMXuuFhz4nEVLw2hvALtecX-AugnWmx02IuF8C1nWCsR8avHSL5bfrr9Glj3kspF73gM2Ijg_R_Ua3CR7dxjN0-frVh_M3k_n7i7fnL-YTIwiXk5JXjTCEaialBcJZ1cxqY-uiFpJBLWvLiJgJXklhZ9yKmTWW8VpaQUXZWMnPULXnHXyndxvdtqqLWXrcKUrU6KdaqdEqlW3bqtFPdeOn2mbs8z22G-o1WAO-j_oHPminfu14t1SL8FnxkpRUkkzw9JYghk8DpF6tXTLQttpDGJKinArJJeOjzie_ja7CEH22JqsjkhHGypHw8c-KDlLunjQPlPsBk-1OEZq_bHv1h20PUOPyg-UfkXdz7X8QbFwLu3--WL18d3mT8u9aZuAG |
| CODEN | BJINFO |
| CitedBy_id | crossref_primary_10_1007_s11547_017_0803_1 crossref_primary_10_1186_s43055_022_00755_7 crossref_primary_10_1111_bju_14049 crossref_primary_10_1371_journal_pone_0157313 crossref_primary_10_1111_bju_13711 crossref_primary_10_1007_s00330_016_4635_5 crossref_primary_10_1038_pcan_2017_34 crossref_primary_10_1056_NEJMoa1910038 crossref_primary_10_1097_RMR_0000000000000081 crossref_primary_10_3349_ymj_2017_58_5_994 crossref_primary_10_1186_s12885_019_6434_2 crossref_primary_10_1016_j_urology_2014_03_012 crossref_primary_10_1016_j_urolonc_2016_02_020 crossref_primary_10_12677_ACM_2023_133698 crossref_primary_10_1155_2014_590638 crossref_primary_10_1245_s10434_016_5438_2 crossref_primary_10_1016_j_ejrad_2014_06_026 crossref_primary_10_1080_13685538_2019_1641796 crossref_primary_10_1097_RCT_0000000000000172 crossref_primary_10_3389_fonc_2023_1102860 crossref_primary_10_1007_s00259_013_2419_6 crossref_primary_10_2214_AJR_13_11061 crossref_primary_10_2214_AJR_15_15768 crossref_primary_10_1002_jmri_25641 crossref_primary_10_2214_AJR_16_16843 crossref_primary_10_1093_jnci_djw039 crossref_primary_10_1097_MOU_0000000000000047 crossref_primary_10_1016_j_brachy_2014_01_011 crossref_primary_10_1590_s1677_5538_ibju_2016_0511 crossref_primary_10_62347_JHYY2053 crossref_primary_10_1002_jmri_24983 crossref_primary_10_1007_s11255_017_1715_7 crossref_primary_10_1007_s11255_017_1670_3 crossref_primary_10_1007_s13244_016_0466_9 crossref_primary_10_1038_aja_2013_39 crossref_primary_10_1007_s11934_015_0507_9 crossref_primary_10_1007_s11934_013_0387_9 crossref_primary_10_1159_000441733 crossref_primary_10_1016_j_urolonc_2021_01_008 crossref_primary_10_1002_cncr_28216 crossref_primary_10_1038_nrclinonc_2014_44 crossref_primary_10_1038_pcan_2017_21 crossref_primary_10_1155_2014_203906 crossref_primary_10_1016_j_acra_2015_02_006 crossref_primary_10_1016_j_juro_2017_02_073 crossref_primary_10_1016_j_pnmrs_2018_01_001 crossref_primary_10_1016_j_ejrad_2017_08_017 crossref_primary_10_1016_j_urology_2016_04_037 crossref_primary_10_1093_jnci_djw040 crossref_primary_10_1111_bju_12639 crossref_primary_10_1016_j_urology_2017_02_027 crossref_primary_10_1007_s00120_012_3096_y crossref_primary_10_1002_pros_24435 crossref_primary_10_1007_s11548_020_02172_5 crossref_primary_10_1016_j_juro_2013_05_118 crossref_primary_10_1111_bju_12335 crossref_primary_10_1007_s00261_017_1135_2 crossref_primary_10_1038_nrurol_2016_26 crossref_primary_10_1097_MD_0000000000011962 crossref_primary_10_1016_j_urology_2016_10_040 crossref_primary_10_1038_s41585_022_00587_0 crossref_primary_10_1016_j_ejrad_2016_11_016 crossref_primary_10_1016_j_euo_2019_08_001 crossref_primary_10_1016_j_juro_2014_10_122 crossref_primary_10_1111_iju_12259 crossref_primary_10_3389_fonc_2023_1092073 crossref_primary_10_1007_s00120_014_3440_5 crossref_primary_10_1007_s11255_016_1212_4 crossref_primary_10_1111_bju_13619 |
| Cites_doi | 10.1016/j.eururo.2010.09.003 10.1016/S0022-5347(01)65201-7 10.3109/10929080802364645 10.1097/01.ju.0000158155.33890.e7 10.1016/j.juro.2011.05.078 10.3322/caac.20073 10.1200/JCO.2003.01.075 10.1016/j.urolonc.2010.08.023 10.1007/s00330-011-2377-y 10.1200/JCO.2010.31.4252 10.1016/j.juro.2010.12.033 10.1002/cncr.22262 10.1038/nrclinonc.2009.18 10.1016/j.juro.2010.10.076 10.1148/radiol.2392050949 10.1016/j.juro.2011.07.013 10.1148/radiol.10100667 10.1016/j.urology.2010.05.044 10.1016/j.juro.2007.07.043 10.1016/j.eururo.2011.08.042 10.1016/j.juro.2007.07.049 |
| ContentType | Journal Article |
| Copyright | 2012 BJU INTERNATIONAL; NO CLAIM TO ORIGINAL US GOVERNMENT WORKS 2012 BJU INTERNATIONAL; NO CLAIM TO ORIGINAL US GOVERNMENT WORKS. BJUI Copyright 2012 BJU International |
| Copyright_xml | – notice: 2012 BJU INTERNATIONAL; NO CLAIM TO ORIGINAL US GOVERNMENT WORKS – notice: 2012 BJU INTERNATIONAL; NO CLAIM TO ORIGINAL US GOVERNMENT WORKS. – notice: BJUI Copyright 2012 BJU International |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QP 7X8 5PM ADTOC UNPAY |
| DOI | 10.1111/j.1464-410X.2012.11646.x |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Calcium & Calcified Tissue Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) Unpaywall for CDI: Periodical Content Unpaywall |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Calcium & Calcified Tissue Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE Calcium & Calcified Tissue Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1464-410X |
| EndPage | E788 |
| ExternalDocumentID | 10.1111/j.1464-410x.2012.11646.x PMC3808160 3024933221 23130821 10_1111_j_1464_410X_2012_11646_x BJU11646 |
| Genre | article Journal Article Comparative Study Research Support, N.I.H., Intramural |
| GrantInformation_xml | – fundername: Intramural NIH HHS grantid: Z01 BC011089 – fundername: Intramural NIH HHS grantid: ZIA BC011081 – fundername: Intramural NIH HHS grantid: ZIE BC011023 – fundername: Division of Basic Sciences : NCI grantid: ZIE BC011023-05 || BC – fundername: Division of Basic Sciences : NCI grantid: Z01 BC011089-01 || BC |
| GroupedDBID | --- .3N .55 .GA .Y3 05W 0R~ 10A 1OB 1OC 23N 2WC 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 6P2 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHQN AAIPD AAMMB AAMNL AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABDBF ABEML ABJNI ABLJU ABOCM ABPVW ABQWH ABXGK ACAHQ ACCZN ACFBH ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACUHS ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN AEFGJ AEIGN AEIMD AENEX AEUYR AEYWJ AFBPY AFEBI AFFNX AFFPM AFGKR AFWVQ AFZJQ AGHNM AGXDD AGYGG AHBTC AHMBA AIACR AIDQK AIDYY AIQQE AITYG AIURR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BAWUL BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DU5 E3Z EAD EAP EBC EBD EBS EJD EMB EMK EMOBN ESX EX3 F00 F01 F04 F5P FUBAC G-S G.N GODZA H.X HF~ HGLYW HZI HZ~ IHE IX1 J0M J5H K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PQQKQ Q.N Q11 QB0 R.K RJQFR ROL RX1 SUPJJ SV3 TEORI TUS UB1 V9Y W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WVDHM WXI WXSBR X7M XG1 YFH ZGI ZXP ~IA ~WT AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QP 7X8 5PM ADTOC UNPAY |
| ID | FETCH-LOGICAL-c5036-839f5c01a266de0329f7bcdb4b562eb6bd205753965d73d57dcd23b6d5158fd63 |
| IEDL.DBID | UNPAY |
| ISSN | 1464-4096 1464-410X |
| IngestDate | Sun Oct 26 02:58:22 EDT 2025 Tue Sep 30 15:46:53 EDT 2025 Thu Oct 02 13:58:07 EDT 2025 Tue Oct 07 06:28:02 EDT 2025 Mon Jul 21 05:29:11 EDT 2025 Wed Oct 01 04:28:58 EDT 2025 Thu Apr 24 22:54:13 EDT 2025 Fri Sep 19 01:20:14 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 11b |
| Language | English |
| License | 2012 BJU INTERNATIONAL; NO CLAIM TO ORIGINAL US GOVERNMENT WORKS. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5036-839f5c01a266de0329f7bcdb4b562eb6bd205753965d73d57dcd23b6d5158fd63 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 content type line 23 |
| OpenAccessLink | https://proxy.k.utb.cz/login?url=https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1464-410X.2012.11646.x |
| PMID | 23130821 |
| PQID | 1406202280 |
| PQPubID | 1026371 |
| ParticipantIDs | unpaywall_primary_10_1111_j_1464_410x_2012_11646_x pubmedcentral_primary_oai_pubmedcentral_nih_gov_3808160 proquest_miscellaneous_1315636236 proquest_journals_1406202280 pubmed_primary_23130821 crossref_primary_10_1111_j_1464_410X_2012_11646_x crossref_citationtrail_10_1111_j_1464_410X_2012_11646_x wiley_primary_10_1111_j_1464_410X_2012_11646_x_BJU11646 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | December 2012 |
| PublicationDateYYYYMMDD | 2012-12-01 |
| PublicationDate_xml | – month: 12 year: 2012 text: December 2012 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: Edgecliff |
| PublicationTitle | BJU international |
| PublicationTitleAlternate | BJU Int |
| PublicationYear | 2012 |
| Publisher | Wiley Subscription Services, Inc |
| Publisher_xml | – name: Wiley Subscription Services, Inc |
| References | 2012; 61 1997; 157 2011; 258 2007; 178 2005; 173 2010; 58 2010; 29 2011; 77 2008; 13 2009; 6 2011; 185 2007; 10 2006; 239 2006; 107 2012; 22 2003; 21 2012; 30 2010; 60 2011; 186 e_1_2_7_6_1 e_1_2_7_5_1 e_1_2_7_4_1 e_1_2_7_3_1 e_1_2_7_9_1 e_1_2_7_7_1 e_1_2_7_19_1 e_1_2_7_18_1 e_1_2_7_17_1 e_1_2_7_16_1 e_1_2_7_2_1 Xu S (e_1_2_7_8_1) 2007; 10 e_1_2_7_15_1 e_1_2_7_14_1 e_1_2_7_13_1 e_1_2_7_12_1 e_1_2_7_23_1 e_1_2_7_11_1 e_1_2_7_22_1 e_1_2_7_10_1 e_1_2_7_21_1 e_1_2_7_20_1 |
| References_xml | – volume: 30 start-page: 301 year: 2012 end-page: 305 article-title: Endorectal T2‐weighted MRI does not differentiate between favorable and adverse pathologic features in men with prostate cancer who would qualify for active surveillance publication-title: Urol Oncol – volume: 13 start-page: 255 year: 2008 end-page: 264 article-title: Real‐time MRI‐TRUS fusion for guidance of targeted prostate biopsies publication-title: Comput Aided Surg – volume: 157 start-page: 559 year: 1997 end-page: 562 article-title: Correlation between Gleason score of needle biopsy and radical prostatectomy specimen: accuracy and clinical implications publication-title: J Urol – volume: 58 start-page: 836 year: 2010 end-page: 837 article-title: Further support for active surveillance in the management of low‐volume, low‐grade prostate cancer publication-title: Eur Urol – volume: 107 start-page: 2384 year: 2006 end-page: 2391 article-title: Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy publication-title: Cancer – volume: 29 start-page: 228 year: 2010 end-page: 234 article-title: Outcomes of active surveillance for men with intermediate‐risk prostate cancer publication-title: J Clin Oncol – volume: 22 start-page: 746 year: 2012 end-page: 757 article-title: ESUR prostate MR guidelines 2012 publication-title: Eur Radiol – volume: 77 start-page: 422 year: 2011 end-page: 426 article-title: Estimation of prostate size in community‐dwelling men publication-title: Urology – volume: 186 start-page: 1818 year: 2011 end-page: 1824 article-title: Multiparametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds publication-title: J Urol – volume: 186 start-page: 1281 year: 2011 end-page: 1285 article-title: Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging publication-title: J Urol – volume: 185 start-page: 1645 year: 2011 end-page: 1649 article-title: Overuse of imaging for staging low risk prostate cancer publication-title: J Urol – volume: 178 start-page: 1925 year: 2007 end-page: 1928 article-title: Predicting the risk of patients with biopsy Gleason score 6 to harbor a higher grade cancer publication-title: J Urol – volume: 10 start-page: 128 year: 2007 end-page: 135 article-title: Closed‐loop control in fused MR‐TRUS image‐guided prostate biopsy publication-title: Med Image Comput Comput Assist Interv – volume: 185 start-page: 815 year: 2011 end-page: 820 article-title: D'Amico risk stratification correlates with degree of suspicion of prostate cancer on multiparametric magnetic resonance imaging publication-title: J Urol – volume: 173 start-page: 1938 year: 2005 end-page: 1942 article-title: The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy publication-title: J Urol – volume: 60 start-page: 277 year: 2010 end-page: 300 article-title: Cancer statistics, 2010 publication-title: CA Cancer J Clin – volume: 178 start-page: 1957 year: 2007 end-page: 1962 article-title: Validity of the CAPRA score to predict biochemical recurrence‐free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients publication-title: J Urol – volume: 239 start-page: 784 year: 2006 end-page: 792 article-title: Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging publication-title: Radiology – volume: 258 start-page: 488 year: 2011 end-page: 495 article-title: Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3‐T MR images? publication-title: Radiology – volume: 61 start-page: 177 year: 2012 end-page: 184 article-title: Prospective assessment of prostate cancer aggressiveness using 3‐T diffusion‐weighted magnetic resonance imaging‐guided biopsies versus a systematic 10‐core transrectal ultrasound prostate biopsy cohort publication-title: Eur Urol – volume: 6 start-page: 197 year: 2009 end-page: 206 article-title: Is it time to consider a role for MRI before prostate biopsy? publication-title: Nat Rev Clin Oncol – volume: 21 start-page: 2163 year: 2003 end-page: 2172 article-title: Cancer‐specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate‐specific antigen era publication-title: J Clin Oncol – ident: e_1_2_7_11_1 doi: 10.1016/j.eururo.2010.09.003 – ident: e_1_2_7_19_1 doi: 10.1016/S0022-5347(01)65201-7 – ident: e_1_2_7_9_1 doi: 10.3109/10929080802364645 – ident: e_1_2_7_17_1 doi: 10.1097/01.ju.0000158155.33890.e7 – ident: e_1_2_7_4_1 doi: 10.1016/j.juro.2011.05.078 – ident: e_1_2_7_2_1 doi: 10.3322/caac.20073 – ident: e_1_2_7_13_1 doi: 10.1200/JCO.2003.01.075 – ident: e_1_2_7_20_1 doi: 10.1016/j.urolonc.2010.08.023 – ident: e_1_2_7_23_1 doi: 10.1007/s00330-011-2377-y – ident: e_1_2_7_14_1 doi: 10.1200/JCO.2010.31.4252 – ident: e_1_2_7_21_1 doi: 10.1016/j.juro.2010.12.033 – ident: e_1_2_7_16_1 doi: 10.1002/cncr.22262 – ident: e_1_2_7_10_1 doi: 10.1038/nrclinonc.2009.18 – ident: e_1_2_7_5_1 doi: 10.1016/j.juro.2010.10.076 – ident: e_1_2_7_7_1 doi: 10.1148/radiol.2392050949 – ident: e_1_2_7_3_1 doi: 10.1016/j.juro.2011.07.013 – ident: e_1_2_7_22_1 doi: 10.1148/radiol.10100667 – volume: 10 start-page: 128 year: 2007 ident: e_1_2_7_8_1 article-title: Closed‐loop control in fused MR‐TRUS image‐guided prostate biopsy publication-title: Med Image Comput Comput Assist Interv – ident: e_1_2_7_12_1 doi: 10.1016/j.urology.2010.05.044 – ident: e_1_2_7_15_1 doi: 10.1016/j.juro.2007.07.043 – ident: e_1_2_7_6_1 doi: 10.1016/j.eururo.2011.08.042 – ident: e_1_2_7_18_1 doi: 10.1016/j.juro.2007.07.049 |
| SSID | ssj0014665 |
| Score | 2.3713872 |
| Snippet | Study Type – Diagnostic (case series)
Level of Evidence 4
What's known on the subject? and What does the study add?
Over‐treatment of indolent prostate cancer... What's known on the subject? and What does the study add? Over-treatment of indolent prostate cancer lesions is a problem which can result in increased human... Study Type - Diagnostic (case series) Level of Evidence-4 What's known on the subject? and What does the study add? Over-treatment of indolent prostate cancer... |
| SourceID | unpaywall pubmedcentral proquest pubmed crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | E783 |
| SubjectTerms | active surveillance Adult Aged Aged, 80 and over Biopsy Humans low suspicion lesion Magnetic Resonance Imaging - methods Male Middle Aged Neoplasm Staging - methods NMR Nuclear magnetic resonance Predictive Value of Tests Prospective Studies Prostate - pathology Prostate cancer prostate MRI Prostatic Neoplasms - diagnosis Reproducibility of Results Risk Factors |
| SummonAdditionalLinks | – databaseName: Wiley Online Library - Core collection (SURFmarket) dbid: DR2 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9NAEF6hHkovUCjQlIIWiasj2_twfAREVUWUAyJSbta-XKqmdhTHSuipP4HfyC9hZu1YclqhCHHzY8b2rGd2v7VnvyHkPYBopTn0fs45GXAYQyGkhA6YTEcmN7HIQ1wofPFVnk_4eCqmbf4TroVp-CG6D24YGb6_xgBXutoOch7wKJxihlYMxyWXQ8STEZN-dvWtY5ICUV9VslEB2N5P6nnwQv2R6h78vJ9F-bgu5urnSs1mfaTrh6qzp-R6Y2SToXI9rJd6aG63-B__TysckictoqUfGhd8Rh654jnZv2j_2R-R2y_lilZ1NYf9sqAzh9_nKgqbTTKjwvQwrBNAb9RlgWsq6cLhBAHckV7d-CpKdL7A6y0pQGwKkJXC42GXRMucIuHy77tfmCMPYqVfIUUNai9ekMnZ5--fzoO24kNghGdGZmkuTBgpgA3WhSxO80Qbq7kGmOa01DZGfMlSKWzCrEissTHT0gIqG-VWspdkrygLd0yotDLSMNcNjXCcKaHkKDIa_NKkyKDvBiTZvN3MtHToWJVjlvWmRTzDps2waTPftNl6QKJOc95Qguygc7pxoKztJCoQDWXs-YgG5F13GsIb_9mowpU1yDCYYAPIYHJAXjX-1t0UoDmSDUVgSs8TOwGkDu-fKa5-eApx5guuwH3jzmf_Yst6y5bEe-TOxmcfxxO_efLPmq_JAR5v8ohOyd5yUbs3gAaX-q2P8z-16FHJ priority: 102 providerName: Wiley-Blackwell |
| Title | Low suspicion lesions on multiparametric magnetic resonance imaging predict for the absence of high‐risk prostate cancer |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1464-410X.2012.11646.x https://www.ncbi.nlm.nih.gov/pubmed/23130821 https://www.proquest.com/docview/1406202280 https://www.proquest.com/docview/1315636236 https://pubmed.ncbi.nlm.nih.gov/PMC3808160 https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1464-410X.2012.11646.x |
| UnpaywallVersion | publishedVersion |
| Volume | 110 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVEBS databaseName: EBSCOhost Academic Search Ultimate customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn eissn: 1464-410X dateEnd: 20241101 omitProxy: true ssIdentifier: ssj0014665 issn: 1464-410X databaseCode: ABDBF dateStart: 19990101 isFulltext: true titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn providerName: EBSCOhost – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1464-410X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0014665 issn: 1464-410X databaseCode: DIK dateStart: 19990101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVWIB databaseName: Wiley Online Library - Core collection (SURFmarket) issn: 1464-410X databaseCode: DR2 dateStart: 19970101 customDbUrl: isFulltext: true eissn: 1464-410X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0014665 providerName: Wiley-Blackwell |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELaqrQRceD8WSmUkrlmS-JHNsSCqqqIrhFhpOUV-hVZsk2izUZee-An8Rn4JM042Iq2EKsTNScaxxhnb3zgznwl5DSBaaQ6zn3NOBhzWUBhSQgdMplOTm1jkISYKn8zk0ZwfL8Rih8y2uTAtP0S_4YYjw8_XOMArm7fz_Js_4nG45AGPwgVGacVwV3I5AUy5KwVg8xHZnc8-HnxpU4xAMExlX4ZKw9Ce7u5m8KrhenUNhF6PpbzdFJX6fqGWyyHe9QvW4T1SblVt41S-TZq1npjLKyyQ_68v7pO7HbalB60xPiA7rnhIbp10f-8fkcsP5QWtm7qC67KgS4c7dTWFYhvWqDBQDE8MoOfqa4HZlXTl0FUAw6Rn5_48JVqt8H1rCmCbAnilStc4OdEyp0i9_OvHT4yWB7HS50pRg7VXj8n88P3nd0dBd_ZDYITnSGZpLkwYKQAQ1oUsTvNEG6u5BsDmtNQ2RqTJUilswqxIrLEx09ICPpvmVrInZFSUhXtGqLQy0uD1hkY4zpRQchoZDRZqUuTSd2OSbL9wZjpidDyfY5kNHCSeYddm2LWZ79psMyZRX7NqyUFuUGdva0RZN13UIBrK2DMTjcmr_jEMdPx7owpXNiDDwNUGuMHkmDxtba5vFEA60g5FoMrAGnsBJBEfPinOTj2ZOPNHr0C7cW-3f9Flc0WXxFvljZXP3h7PffH5vzT3gtzByzaYaI-M1qvGvQRIuNb74Ax9ive70f4bfV5Xhw |
| linkProvider | Unpaywall |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQkSiX8oalBYzENaskjp3NsTyqpez2gLrS3iK_UirSZLXZqI8TP6G_kV_SGScbKVuEKsQtj5lE48zYn53xN4R8ABAtVQS9n7VWeBGMoRBSXHlMJCOd6ZBnPm4Unh6J8Sw6nPN5Ww4I98I0_BDdghtGhuuvMcBxQXozyiMvCvw5pmiFcF1EYgiA8j5c99HFP3_vuKRA1tWVbHQAuPfTev74pP5YdQuA3s6j3K6Lhbw8l3nex7pusDp4RPK1mU2Oys9hvVJDfbXBAPmf2uEx2WlBLd1vvPAJuWeLp-TBtP1t_4xcTcpzWtXVAs7LguYWl-gqCodNPqPEDDEsFUDP5EmB2yrp0uIcATySnp65Qkp0scTnrSigbAqolUpVYa9Ey4wi5_LvX9eYJg9ipdskRTVqL5-T2cGX409jry364GnuyJFZknHtBxKQg7E-C5MsVtqoSAFSs0ooEyLEZIngJmaGx0abkClhAJiNMiPYC7JVlIV9RagwIlAw3fU1txGTXIpRoBW4pk6QRN8OSLz-vKluGdGxMEee9mZGUYpNm2LTpq5p04sBCTrNRcMKcgedvbUHpW0_UYGoL0JHSTQg77vbEOH420YWtqxBhsEcG3AGEwPysnG47qWAzpFvKABTeq7YCSB7eP9OcfrDsYgzV3MF3ht2TvsXWy42bImdS97Z-PTj4cwdvv5nzXdke3w8naSTr0ffdslDlGnSivbI1mpZ2zcADlfqrQv6G89aVeo |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQkQoXypstBYzEdVdJ_MjmCJRVKW2FECvtLfIrUJEm0Wajlp74CfxGfgkzTjZStghViFseM7HGmbE_J-NvCHkFIFppDqOfc06OOcyhEFJCj5lMpiYzkcgC3Ch8fCIP5vxwIRZdOSDcC9PyQ_Qf3DAy_HiNAe4qm21GOR_zMFhgilYE1yWXEwCUN7lIppjft_-p55ICWV9XstUB4D5M6_njk4Zz1RUAejWP8lZTVOr7ucrzIdb1k9Vsh-RrM9sclW-TZqUn5nKDAfI_9cNdcqcDtfR164X3yA1X3Cfbx91v-wfk8qg8p3VTV3BeFjR3-ImupnDY5jMqzBDDUgH0TH0pcFslXTpcI4BH0tMzX0iJVkt83ooCyqaAWqnSNY5KtMwoci7_-vET0-RBrPSbpKhB7eVDMp-9-_z2YNwVfRgb4cmRWZIJE4QKkIN1AYuSLNbGaq4BqTkttY0QYrJEChszK2JrbMS0tADMppmV7BHZKsrCPSFUWhlqWO4GRjjOlFByGhoNrmkSJNF3IxKvX29qOkZ0LMyRp4OVEU-xa1Ps2tR3bXoxImGvWbWsINfQ2Vt7UNqNEzWIBjLylEQj8rK_DRGOv21U4coGZBissQFnMDkij1uH6xsFdI58QyGYMnDFXgDZw4d3itOvnkWc-Zor0G7UO-1fbLnYsCX2Lnlt49M3h3N_uPvPmi_I9sf9WXr0_uTDU3IbRdqsoj2ytVo27hlgw5V-7mP-NwJHVW4 |
| linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELaqrQRceD-2FGQkrlmS-JHNsSCqqqIrDqy0nCK_AlW3SbTZqEtP_Qn8Rn4JM042Iq2EKsTNScaxxpmxPzsznwl5CyBaaQ6jn3NOBhzmUHApoQMm06nJTSzyEBOFT2byaM6PF2KxQ2bbXJiWH6LfcEPP8OM1Onhl83acf_dHPA6XPOBRuMAorRjuSi4ngCl3pQBsPiK789nng69tihEIhqnsy1BpGNrT3d0MXjWcr26A0JuxlHebolI_LtRyOcS7fsI6fEDKraptnMrZpFnribm8xgL5__riIbnfYVt60BrjI7Ljisfkzkn39_4JufxUXtC6qSu4Lgu6dLhTV1MotmGNCgPF8MQAeq6-FZhdSVcOlwpgmPT03J-nRKsVvm9NAWxTAK9U6RoHJ1rmFKmXf139xGh5ECt9rhQ1WHv1lMwPP375cBR0Zz8ERniOZJbmwoSRAgBhXcjiNE-0sZprAGxOS21jRJoslcImzIrEGhszLS3gs2luJXtGRkVZuBeESisjDave0AjHmRJKTiOjwUJNilz6bkyS7RfOTEeMjudzLLPBAoln2LUZdm3muzbbjEnU16xacpBb1NnfGlHWDRc1iIYy9sxEY_KmfwyOjn9vVOHKBmQYLLUBbjA5Js9bm-sbBZCOtEMRqDKwxl4AScSHT4rT755MnPmjV6DduLfbv-iyuaZL4q3y1spn74_nvrj3L829JPfwsg0m2iej9apxrwASrvXrzs9_A3YCVp4 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Low+suspicion+lesions+on+multiparametric+magnetic+resonance+imaging+predict+for+the+absence+of+high-risk+prostate+cancer&rft.jtitle=BJU+international&rft.au=Yerram%2C+Nitin+K&rft.au=Volkin%2C+Dmitry&rft.au=Turkbey%2C+Baris&rft.au=Nix%2C+Jeffrey&rft.date=2012-12-01&rft.pub=Wiley+Subscription+Services%2C+Inc&rft.issn=1464-4096&rft.eissn=1464-410X&rft.volume=110&rft.issue=11b&rft.spage=E783&rft_id=info:doi/10.1111%2Fj.1464-410X.2012.11646.x&rft.externalDBID=NO_FULL_TEXT&rft.externalDocID=3024933221 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1464-4096&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1464-4096&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1464-4096&client=summon |